PURPOSE: To evaluate the role of allogeneic bone marrow transplantation (BMT) in recurrent low-grade lymphoma. PATIENTS AND METHODS: Between 1989 and 1994, 10 patients with chemotherapy-refractory and recurrent low-grade lymphoma were treated with myeloablative therapy and allogeneic BMT. All patients had poor prognostic features and had been extensively pretreated. RESULTS: Eight patients achieved a complete remission and none have relapsed at a median follow-up time of 816 days (range, 346 to 1,865). Two patients died of early complications. The actuarial survival and failure-free survival rates are both 80% +/- 12.6%. For surviving patients, the duration of the current remission exceeds that of any previous remission achieved. CONCLUSION: These results compare favorably with those for autologous BMT. Allogeneic BMT offers considerable promise for the treatment of patients with poor-prognosis low-grade lymphoma. Its role should be further defined in prospective studies.
PURPOSE: To evaluate the role of allogeneic bone marrow transplantation (BMT) in recurrent low-grade lymphoma. PATIENTS AND METHODS: Between 1989 and 1994, 10 patients with chemotherapy-refractory and recurrent low-grade lymphoma were treated with myeloablative therapy and allogeneic BMT. All patients had poor prognostic features and had been extensively pretreated. RESULTS: Eight patients achieved a complete remission and none have relapsed at a median follow-up time of 816 days (range, 346 to 1,865). Two patients died of early complications. The actuarial survival and failure-free survival rates are both 80% +/- 12.6%. For surviving patients, the duration of the current remission exceeds that of any previous remission achieved. CONCLUSION: These results compare favorably with those for autologous BMT. Allogeneic BMT offers considerable promise for the treatment of patients with poor-prognosis low-grade lymphoma. Its role should be further defined in prospective studies.
Authors: Parameswaran Hari; Jeanette Carreras; Mei-Jie Zhang; Robert Peter Gale; Brian J Bolwell; Christopher N Bredeson; Linda J Burns; Mitchell S Cairo; César O Freytes; Steven C Goldstein; Gregory A Hale; David J Inwards; Charles F Lemaistre; Dipnarine Maharaj; David I Marks; Harry C Schouten; Shimon Slavin; Julie M Vose; Hillard M Lazarus; Koen van Besien Journal: Biol Blood Marrow Transplant Date: 2008-02 Impact factor: 5.742
Authors: F Heinzelmann; W Bethge; D W Beelen; M Engelhard; N Kröger; P Dreger; D Niederwieser; J Finke; D Bunjes; J Tischer; G Kobbe; E Holler; M Bornhäuser; M Stelljes; H Baurmann; A Müller; I Haubitz; H Schrezenmeier; C Müller; H Ottinger Journal: Bone Marrow Transplant Date: 2016-02-08 Impact factor: 5.483